Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANTAGE: Cilengitide in SCCHN
NCT00705016Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2008
- Primary completion
- Sep 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of cilengitide in squamous cell carcinoma of the head and neck (HNSCC) (3 arms), sponsored by Merck KGaA. Primary endpoint: Progression-free Survival Time. Started Oct 2008; status: completed.
02
Drugs
cilengitide
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00705016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705016.